

FY 2017 Government Performance and Results Act (GPRA)

INDIAN HEALTH SERVICE (IHS) GPRA PERFORMANCE RESULTS

Introduction

IHS clinical GPRA results are calculated from the Clinical Reporting System (CRS) Class 1 software module installed locally on the Resource and Patient Management System (RPMS), IHS's electronic health record.

The CRS measure logic is located [here](#)

Each clinical measure has two graphs:

- the current national performance result and historical data
- IHS Area graphs comparing the current reporting year to the previous year for each of IHS's twelve Area Offices.

Area Abbreviations

Abbreviation	Area
ALA	Alaska
ALB	Albuquerque
BEM	Bemidji
BIL	Billings
CAL	California
GPA	Great Plains
NAS	Nashville
NAV	Navajo
OKL	Oklahoma
PHO	Phoenix
POR	Portland
TUC	Tucson

Acronym Definitions

Acronym	Definition
NPIRS	National Patient Information Registrations System
AI/AN	American Indian/Alaska Native
A1c	Hemoglobin A1c
BMI	Body Mass Index
BP	Blood Pressure
CHD	Coronary Heart Disease
CVD	Cardiovascular Disease
DV/IPV	Domestic Violence/Intimate Partner Violence
HP	Healthy People
IHD	Ischemic Heart Disease
LDL	Low Density Lipoprotein
MH	Million Hearts
HIV	Human Immunodeficiency Virus
SBIRT	Screening, Brief Intervention, & Referral to Treatment

GPRRA 2017 Results Summary

Of the 27 measures that IHS/Tribal programs reported in FY 2017:

- 16 measures exceeded FY 2016 results
- 4 measures decreased from FY 2016 results
- 1 measure had no change from FY 2016 results
- 6 measures were new for FY 2017 and had baseline targets
- One GPRAMA measure (CVD Statin Therapy) had a baseline target, and therefore met the measure target
- Three GPRAMA measures (Good Glycemic Control, Depression Screening 18+, and Childhood IZ) did not meet targets; both Good Glycemic Control and Childhood IZ also decreased in performance, whereas Depression Screening 18+ improved in performance from 2016

3 of the 4 measures that decreased did not meet targets, however:

- Controlled BP <140/80 decreased from 2016 performance but still met the 2017 target
- Retinopathy Exam, Dental Access, Mammography, Tobacco Cessation, and Depression Screening 18+ all exceeded 2016 results but did not meet 2017 targets

FY 2017 IHS/Tribal Results Summary

In FY 2017, 16 measures improved over FY 2016 performance

Measure	FY 2016 Q4	FY 2017 Q4	% Improvement
Breastfeeding Rates	35.2%	40.1%	4.9%
HIV Screening	41.9%	45.1%	3.2%
Diabetes: Statin Therapy	61.9%	64.2%	2.3%
Retinopathy Exam	59.1%	61.4%	2.3%
Colorectal Cancer Screening	39.6%	41.4%	1.8%
Tobacco Cessation	50.4%	52.2%	1.8%
Depression Screening 18+	67.9%	69.4%	1.5%
DV/IPV Screening	65.3%	66.6%	1.3%
Nephropathy Assessed	63.3%	64.5%	1.2%
Topical Fluorides	31.1%	31.9%	0.8%
Dental Access	28.7%	29.5%	0.8%
Mammography	54.8%	54.8%	0.6%
Influenza Vaccination 18+	38.7%	39.2%	0.5%
Dental Sealants	18.1%	18.5%	0.4%
Pneumococcal Vaccination 65+	86.4%	86.8%	0.4%
Influenza Vaccination 6mo - 17yrs	37.1%	37.2%	0.1%


FY 2017 IHS/Tribal Results Summary

In FY 2017, 4 measures decreased compared to FY 2016 performance


Measure	FY 2016 Q4	FY 2017 Q4	% Decrease
Childhood Immunizations	72.3%	70.9%	1.4%
Good Glycemic Control	46.9%	46.1%	2.3%
Controlled BP <140/90	68.3%	67.6%	0.7%
Controlling High BP (MH)	59.2%	59.0%	0.2%

Diabetes: Good Glycemic Control

AI/AN patients with diabetes who have maintained Good A1c control (<8) during the past year.




Diabetes: Good Glycemic Control




Diabetes: Blood Pressure Control

AI/AN patients with diabetes who have maintained BP control (<140/90) during the past year.




*Minor logic change in FY 2016 to include patients with only one BP recorded during the report period.

Diabetes: Blood Pressure Control (<140/90)




Diabetes: Statin Therapy to Prevent Cardiovascular Disease Risk

AI/AN patients with diabetes who are statin therapy users or receive a prescription for statin therapy during the report period.




Diabetes: Statin Therapy to Prevent CVD Risk




Diabetes: Nephropathy Assessment

AI/AN patients with diabetes who have been assessed for nephropathy within the past year.




* New baseline set to reflect measure change requiring UACR in FY 2014.

Diabetes: Nephropathy Assessment




Diabetes: Retinopathy

AI/AN patients with diabetes who have been assessed for retinopathy within the past year.




*Minor logic change in FY 2016 to exclude chart reviews and telephone calls from counting towards meeting the measure

Diabetes: Retinopathy




Dental: General Access

AI/AN patients who have received dental services within the past year.




Dental: General Access




Dental: Sealants

AI/AN children with intact dental sealants.




Dental: Sealants




Dental: Topical Fluorides

AI/AN children with at least one topical fluoride treatment within the past year.




*Prior to FY 2013, this measure tracked the number of patients receiving one or more fluoride applications in the past year.

Dental: Topical Fluorides




Immunizations: Influenza 6mo - 17yrs

AI/AN patients (ages 6 months to 17 years) who have received the influenza vaccine within the past year.




* New measure in FY 2016.

Immunizations: Influenza 6mo – 17yr




Immunizations: Influenza 18+

AI/AN patients (ages 18+) who have received the influenza vaccine within the past year.




* New measure in FY 2016.

Immunizations: Influenza 18+




Immunizations: Pneumococcal

AI/AN patients (age 65+) with pneumo vaccine after the age of 65 or a dose of pneumo vaccine in the past five years.




*New baseline in FY 2014 due to measure logic change

Immunization: Pneumococcal 65+




Immunizations: Childhood (19-35 months)

AI/AN patients (age 19-35 months) who have received the combined childhood vaccination series (4:3:1:3*:3:1:4).




* 1 Varicella vaccine added to the series in FY 2010. **4 Pneumococcal conjugate vaccines were added to the series in FY 2011. ***In FY 2013, 3 or 4 HiB vaccines were required depending on the brand.

Immunizations: Childhood (19-35 months)




Cancer Screening: Cervical (Pap Screen)

AI/AN women age 24-64 who have received a Pap screen within the previous three years, or age 30-64 years with a Pap screen in the past three years or a Pap Screen and an HPV DNA in the past five years.




Cancer Screening: Cervical (Pap Screen)




Cancer Screening: Breast (Mammography)

AI/AN women (age 52-64) who have received mammography screening within the previous two years.




Cancer Screening: Breast (Mammography)




Cancer Screening: Colorectal

AI/AN patients ages 50-75 who have received appropriate Colorectal Cancer Screening.




Cancer Screening: Colorectal




Tobacco Cessation

AI/AN tobacco-using patients who have received tobacco cessation intervention within the past year or quit their tobacco use within the past year.




Tobacco Cessation




Universal Alcohol Screening

AI/AN patients ages 12-75 who have been screened for alcohol use within the past year.




*New measure in FY 2017.

Universal Alcohol Screening




Screening, Brief Intervention, Referral to Treatment (SBIRT)

AI/AN patients ages 9-75 who screened positive for alcohol use and were provided a brief intervention or brief negotiated interview within seven days of the positive screen




*New measure in FY 2017.

SBIRT




Domestic Violence/Intimate Partner Violence Screening:

AI/AN women (age 14-46) who were screened for domestic violence /intimate partner violence within the past year.




*Prior to FY 2016, this measure tracked the percentage of female patients ages 15-40 who had received DV/IPV Screening in the past year.

DV/IPV Screening




Depression Screening 12-17

AI/AN patients ages 12-17 who have been screened for depression or diagnosed with a mood disorder within the past year.




*New measure in FY 2017

Depression Screening 12 – 17 years




Depression Screening 18+

AI/AN patients ages 18 and older who have been screened for depression or diagnosed with a mood disorder within the past year.




Depression Screening 18+




Antidepressant Medication Management (Acute)

AI/AN patients diagnosed with depression who received a prescription for an antidepressant with enough medication to last for 12 weeks




*New measure in FY 2017.

Antidepressant Medication Management (Acute)




Antidepressant Medication Management (Continuous)
AI/AN patients diagnosed with depression who received a prescription for
an antidepressant with enough medication to last for 6 months




*New measure in FY 2017.

Antidepressant Medication Management (Cont.)




Childhood Weight Control (CWC)

AI/AN children ages 2-5 years with a BMI at or above 95th percentile.




Childhood Weight Control




HIV Screening Ever

AI/AN patients who have ever received screening for HIV.




*New measure in FY 2016

HIV Screening Ever




CVD Statin Therapy

Patients age 40 to 75 with diabetes, or age 21 and older with documented CVD or an LDL greater than or equal to 190 who are statin therapy users or receive a prescription for statin therapy




*New measure in FY 2017

CVD Statin Therapy




Controlling High Blood Pressure (MH)

AI/AN patients with diagnosed hypertension who have achieved blood pressure control (<140/90).




Controlling High Blood Pressure (MH)




Breastfeeding Rates

AI/AN patients who, at the age of two months, were either exclusively or mostly breastfed.



Breastfeeding Rates



2017 Final National Dashboard (IHS/Tribal)

DIABETES	2016 Target	2016 Final	2017 Target	2017 Final	2017 Final Results
Good Glycemic Control	49.5%	46.9%	48.4%	46.1%	Not Met
Controlled Blood Pressure <140/90	65.0%	68.3%	63.8%	67.6%	Met
Statin Therapy	Baseline	61.9%	61.9%	64.2%	Met
Nephropathy Assessed	61.1%	63.3%	63.3%	64.5%	Met
Retinopathy Exam	61.6%	59.1%	63.1%	61.4%	Not Met
DENTAL					
Dental: General Access	29.3%	28.7%	29.7%	29.5%	Not Met
Sealants	14.8%	18.1%	16.6%	18.5%	Met
Topical Fluoride	28.3%	31.1%	29.9%	31.9%	Met
IMMUNIZATIONS					
Influenza Vaccination 6 months - 17 years	Baseline	37.1%	37.1%	37.2%	Met
Influenza Vaccination 18+	Baseline	38.7%	38.7%	39.2%	Met
Pneumococcal Vaccination 65+	87.3%	86.4%	86.7%	86.8%	Met
Childhood IZ	76.8%	72.3%	74.8%	70.9%	Not Met
PREVENTION					
(Cervical) Pap Screening	55.6%	54.8%	56.1%	54.8%	Not Met
Mammography Screening	55.9%	54.8%	56.7%	55.4%	Not Met
Colorectal Cancer Screening	38.7%	39.6%	40.2%	41.4%	Met
Tobacco Cessation	49.1%	50.4%	53.2%	52.2%	Not Met
Universal Alcohol Screening ^a	N/A	N/A	Baseline	68.0%	Met
Screening, Brief Intervention & Referral to Treatment ^a	N/A	N/A	Baseline	3.0%	Met
Intimate Partner Violence/Domestic Violence Screening	Baseline	65.3%	65.3%	66.6%	Met
Depression Screening 12 - 17 years ^a	N/A	N/A	Baseline	50.1%	Met
Depression Screening 18+	67.2%	67.9%	70.0%	69.4%	Not Met
Antidepressant Medication Management: Acute ^a	N/A	N/A	Baseline	41.9%	Met
Antidepressant Medication Management: Continuous ^a	N/A	N/A	Baseline	21.9%	Met
Childhood Weight Control ^b	22.8%	22.3%	N/A	22.8%	N/A
Controlling High Blood Pressure (Million Hearts)	60.6%	59.2%	59.7%	59.0%	Not Met
CVD Statin Therapy^a	N/A	N/A	Baseline	48.1%	Met
HIV Screen Ever	Baseline	41.9%	41.9%	45.1%	Met
Breastfeeding Rates	35.8%	35.2%	36.4%	40.1%	Met

^aNew measure as of FY 2017

^bLong-term measure; next reported in FY 2019

Measures Met: 18

Measures Not Met: 9

Measures in red are GPRAMA measures